We're happy to welcome Ellie (PhD student), Muye (PhD student), and Charlie (5P student) to the group. We wish them the best of luck with their projects!
Last week, some members of the ESMB group attended the Synuclein meeting 2025 to hear about current and future approaches to target synulceinopathies. This event offered a very varied programme, with talks ranging from clinical and pre-clinical studies in the field of Parkinson’s disease and Multiple System Atrophy all the way to super-resolution imaging of aSynuclein aggregates. It was an amazing experience to get to hear from groups that have changed this field over the years and also to see all the new projects being set up to study these diseases onset and progression, therapies and diagnosis. It felt like going back to the origins of the group, where it all started! Finally, Gala dinner/party at King’s College Hall was definitely a highlight of the programme.
Researchers from the ESMB have developed a single-molecule liposome assay that promises to transform the study of membrane disruption by proteins and peptides. Their innovative method, funded by the Leverhulme Trust, addresses longstanding challenges in membrane-related research across antimicrobial activity, toxicity, and disease pathology. Membrane integrity is crucial for cellular health, playing a vital role in processes such as ion transport and signal transmission. Disruption of these membranes is linked to various disorders, including Alzheimer's and Parkinson’s disease, and certain cancers. Traditional techniques for examining the membrane-disrupting effects of proteins and peptides can be challenging and often require larger quantities, which are costly and difficult to produce. Their new approach uses single-molecule confocal microscopy with fast-flow microfluidics to detect membrane disruption with minimal quantities of proteins and peptides. This method provides unparal...
To showcase their work funded and supported by UCB, Beccy, Ji-Eun and Mathew recently visited UCB Biopharma near Waterloo in Belgium. They met Patrick Downey, Rachel Angers and the rest of the UCB neurodegeneration team, and explained to them how their new assays for detecting protein aggregates worked. They also had the opportunity to have a tour of the labs, learning about how industry are investigating neurodegeneration.
Comments
Post a Comment